HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masakazu Fukushima Selected Research

Trifluridine (Viroptic)

6/2014The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
5/2010Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
2/2010Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
10/2008Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
1/2007Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
1/2006Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
3/2005Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masakazu Fukushima Research Topics

Disease

98Neoplasms (Cancer)
12/2019 - 01/2002
19Colorectal Neoplasms (Colorectal Cancer)
01/2017 - 08/2002
16Colonic Neoplasms (Colon Cancer)
08/2012 - 08/2002
14Carcinoma (Carcinomatosis)
06/2010 - 04/2002
11Stomach Neoplasms (Stomach Cancer)
12/2019 - 12/2002
8Breast Neoplasms (Breast Cancer)
09/2008 - 01/2002
5Neoplasm Metastasis (Metastasis)
12/2019 - 01/2002
5Pancreatic Neoplasms (Pancreatic Cancer)
04/2010 - 09/2004
5Lung Neoplasms (Lung Cancer)
01/2010 - 12/2003
4Ovarian Neoplasms (Ovarian Cancer)
12/2019 - 05/2003
4Body Weight (Weight, Body)
12/2019 - 08/2005
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2014 - 02/2004
4Squamous Cell Carcinoma of Head and Neck
02/2009 - 01/2007
4Adenocarcinoma
10/2006 - 02/2002
4Renal Cell Carcinoma (Grawitz Tumor)
02/2004 - 02/2003
3Malignant Mesothelioma
11/2016 - 06/2006
3Fibrosarcoma
10/2007 - 01/2002
2Ascites
06/2019 - 01/2018
2Virus Diseases (Viral Diseases)
11/2010 - 01/2007
1Leukemia
03/2018
1Thrombocytopenia (Thrombopenia)
01/2017

Drug/Important Bio-Agent (IBA)

66Fluorouracil (Carac)FDA LinkGeneric
01/2017 - 01/2002
32Thymidylate SynthaseIBA
12/2019 - 01/2002
19EnzymesIBA
10/2010 - 01/2002
18Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA
01/2017 - 01/2002
16Proteins (Proteins, Gene)FDA Link
05/2011 - 07/2002
14Messenger RNA (mRNA)IBA
01/2018 - 07/2002
12DNA (Deoxyribonucleic Acid)IBA
03/2018 - 04/2004
11Pharmaceutical PreparationsIBA
03/2018 - 08/2002
11Orotate PhosphoribosyltransferaseIBA
01/2017 - 02/2004
9Thymidine PhosphorylaseIBA
02/2016 - 12/2002
9TegafurIBA
11/2010 - 07/2005
81- (3- C- ethynylribopentofuranosyl)cytosineIBA
01/2017 - 01/2002
7Small Interfering RNA (siRNA)IBA
06/2019 - 05/2011
7Paclitaxel (Taxol)FDA LinkGeneric
01/2018 - 01/2002
7Trifluridine (Viroptic)FDA LinkGeneric
06/2014 - 03/2005
7ProdrugsIBA
11/2010 - 12/2002
7UracilIBA
11/2010 - 07/2005
7trifluridine tipiracil drug combinationIBA
10/2008 - 04/2004
6NucleosidesIBA
03/2018 - 04/2002
6Folic Acid (Vitamin M)FDA LinkGeneric
02/2016 - 01/2006
6Irinotecan (Camptosar)FDA LinkGeneric
02/2016 - 06/2006
6Antineoplastic Agents (Antineoplastics)IBA
06/2014 - 08/2002
6Capecitabine (Xeloda)FDA Link
08/2008 - 12/2004
5Cisplatin (Platino)FDA LinkGeneric
11/2010 - 04/2006
4GemcitabineFDA Link
03/2018 - 05/2005
4Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2017 - 06/2007
4Biomarkers (Surrogate Marker)IBA
01/2015 - 09/2003
4gimeracilIBA
09/2011 - 08/2010
4Leucovorin (Folinic Acid)FDA Link
05/2011 - 03/2007
4Docetaxel (Taxotere)FDA Link
06/2010 - 06/2006
4TransferasesIBA
07/2007 - 05/2005
4Taxoids (Taxanes)IBA
06/2006 - 01/2002
3Liposomes (Liposome)IBA
01/2018 - 04/2016
3RNA (Ribonucleic Acid)IBA
01/2017 - 01/2002
3Biological ProductsIBA
02/2016 - 08/2008
3ErbB Receptors (EGF Receptor)IBA
02/2016 - 04/2006
32-5A-dependent ribonuclease (RNase L)IBA
11/2010 - 01/2006
3Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
10/2010 - 04/2006
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2007 - 12/2002
3AntimetabolitesIBA
06/2007 - 04/2004
3titanium silicide (TS-1)IBA
03/2007 - 09/2004
3Thymidine KinaseIBA
01/2007 - 11/2002
3ImmunosorbentsIBA
06/2006 - 05/2004
3doxifluridineIBA
06/2006 - 01/2002
2DFP-10825IBA
12/2019 - 01/2018
2CytosineIBA
03/2018 - 04/2009
2Uridine KinaseIBA
01/2017 - 07/2002
2RNA Polymerase I (Polymerase I, RNA)IBA
01/2017 - 11/2010
2Pemetrexed (MTA)FDA Link
11/2016 - 04/2016
2Type I DNA Topoisomerases (Topoisomerase I)IBA
02/2016 - 01/2007
2folylpolyglutamate synthetaseIBA
02/2016 - 05/2011
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2016 - 05/2003
2ThymidineIBA
05/2012 - 10/2008
2polyacrylamideIBA
11/2010 - 08/2008
2Erlotinib Hydrochloride (CP 358,774)FDA Link
02/2010 - 04/2006
2Complementary DNA (cDNA)IBA
02/2009 - 01/2009
2Thrombospondin 1IBA
10/2008 - 08/2008
2PlatinumIBA
09/2008 - 06/2007
2potassium oxonateIBA
08/2008 - 07/2005
2Cytotoxins (Cytolysins)IBA
06/2007 - 09/2003
2Uridine PhosphorylaseIBA
01/2007 - 12/2002
2pyrimidineIBA
01/2007 - 09/2003
2Peptides (Polypeptides)IBA
08/2005 - 05/2005
2Indicators and Reagents (Reagents)IBA
02/2004 - 03/2002
1A-Form DNA (A-DNA)IBA
03/2018
1DeoxycytidineIBA
03/2018
1DFP-10917IBA
03/2018
1Cytarabine (Cytosar-U)FDA LinkGeneric
03/2018
1LuciferasesIBA
01/2018
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
01/2017
1DFP-11207IBA
01/2017

Therapy/Procedure

30Drug Therapy (Chemotherapy)
12/2019 - 02/2003
21Therapeutics
12/2019 - 08/2002
4Radiotherapy
05/2012 - 09/2006
4Oral Administration
10/2008 - 08/2005
4Adjuvant Chemotherapy
08/2007 - 12/2006
2RNAi Therapeutics
12/2019 - 06/2019
2Intravenous Administration
10/2017 - 11/2016
1Intraperitoneal Injections
12/2019